Wegovy vs. Zepbound: Which GLP-1 Is Right for You?

Wegovy and Zepbound are the two most-prescribed branded weight-loss injections in the U.S. They're related but not identical. Here's a clear comparison.

Different molecules, different targets

• Wegovy is semaglutide — a GLP-1 receptor agonist.
• Zepbound is tirzepatide — a dual GIP and GLP-1 receptor agonist.

That second receptor (GIP) is why many patients and trials see larger average weight loss with tirzepatide, though individual results vary widely.

Average weight loss (clinical trials)

Numbers come from manufacturer trials; your result depends on dose, diet, and adherence.

Side effects

Both share the GLP-1 class side effects — nausea, constipation, and reduced appetite — usually strongest when starting or increasing a dose. Tirzepatide's GI effects can feel stronger for some people early on. Titrating slowly helps.

Cost

Both carry similar list prices ($1,000–$1,400/mo cash). What you actually pay depends on the clinic, savings cards, and whether you choose brand vs. compounded. See our cost guide for the real ranges.

How to decide

There's no universal "better" — it depends on your medical history, insurance, tolerance, and goals. Bring this comparison to a provider and ask which fits you.

Compare Wegovy vs. Zepbound clinics →

Sources

• Wegovy prescribing information (Novo Nordisk)
• Zepbound prescribing information (Eli Lilly)
• STEP-1 trial (NEJM 2021) — Wegovy 2.4 mg weight-loss data
• SURMOUNT-1 trial (NEJM 2022) — Zepbound (tirzepatide) weight-loss data
• FDA Drugs@FDA label database — official approval records for both
• NHLBI clinical obesity guidelines — comorbidity eligibility criteria

General information, not medical advice. A licensed clinician should guide your treatment.